recombinant human pro-EMAPII/p43 (Shanghai Sine Pharmaceutical)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namerecombinant human pro-EMAPII/p43 (Shanghai Sine Pharmaceutical)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytokine receptors agonists
TargetsCytokine receptors
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Xinyi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMitsubishi Tanabe Pharma CorpShanghai Xinyi Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A